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The high energetic demand of the brain deems this organ rather sensitive to changes in energy supply.
Therefore, even minor alterations in energy metabolism may underlie detrimental disturbances in brain
function, contributing to the generation and progression of neurodegenerative diseases. Considerable
evidence supports the key role of deficits in cerebral energy metabolism, particularly hypometabolism of
glucose and mitochondrial dysfunction, in the pathophysiology of brain disorders. Major breakthroughs in the
field of bioenergetics and neurodegeneration have been achieved through the use of in vitro and in vivo
models of disease as well as sophisticated neuroimaging techniques in patients, yet these have been mainly
focused on neuron and astrocyte function. Remarkably, the subcellular metabolic mechanisms linked to
neurodegeneration that operate in other crucial brain cell types such as microglia have remain obscured,
although they are beginning to be unraveled. Microglia, the brain-resident immune sentinels, perform a
diverse range of functions that require a high-energy expenditure, namely, their role in brain development,
maintenance of the neural environment, response to injury and infection, and activation of repair programs.
Interestingly, another key mechanism underlying several neurodegenerative diseases is neuroinflammation,
which can be associated with chronic microglia activation. Considering that many brain disorders are
accompanied by changes in brain energy metabolism and sustained inflammation, and that energy
metabolism has a strong influence on the inflammatory responses of microglia, the emerging significance of
microglial energy metabolism in neurodegeneration is highlighted in this review.
© 2019 Elsevier Ltd. All rights reserved.Introduction
The multifaceted functions of the central nervous
system (CNS) require a healthy microenvironment
for brain cells to thrive. The maintenance of such
milieu critically depends on microglia, the CNS
innate immune cells [1,2]. Microglia are among the
most versatile cells in the human body, as they elicit
diverse actions critical for the development and
homeostasis of the brain. Upon detection of injury or
infection, microglia undergo morphological and
functional transformations, and rapidly respond to
overcome brain insults. This response is known as
microglial activation and involves patterned actions
including migration to the site of injury and release of
immune response molecules such as cytokines,
proteases, and reactive oxygen species (ROS)r Ltd. All rights reserved.[1,3–5]. Evidence indicates that depending on their
activation profile, microglia can promote neuronal
survival or lead to neuronal degeneration [3,6–8].
Furthermore, either a sustained or a deficient
microglia-derived inflammatory response can be
detrimental to the brain. Given the vital role of
microglia in normal CNS function, it is not surprising
that several brain disorders are associated with
microglia dysfunction. In line with this, exacerbated
microglia activation has been implicated in neurode-
generative diseases, and it has been suggested that
microglia-dependent neuroinflammation may con-
tribute to neurodegeneration [6,9,10]; the specific
underlying mechanisms, however, remain elusive.
It is well established that the brain is an energet-
ically expensive organ. The majority of the fuel
supply for the brain is utilized to meet the high-Journal of Molecular Biology (2019) 431, 1830–1842
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[11]. However, experimental evidence indicates that
an important fraction of the energy consumption in
the brain is not directly related to information
processing. Although little is known regarding the
brain functions that are so energetically costly, it has
been suggested that microglia surveillance and
activation could place a considerable strain on the
energy budget [12]. Interestingly, impairments in
energy processing have been strongly linked to
hampered brain function and neurodegeneration
[13–15]. Specifically, decreased metabolism of
glucose, the obligatory energy substrate in the
brain, is widely accepted as an early hallmark in
neurodegenerative diseases [16–18].
Another well-recognized factor contributing to the
progression of neurodegenerative disorders is neu-
roinflammation [19], where the exacerbated inflam-
matory response in the brain is predominantly
attributed to microglia. Whether microglia activation
is a cause or an effect of disease-associated
neurodegeneration is currently under intense scruti-
ny and debate. Specific mechanisms by which
microglia contributes to inflammation-induced neuro-
degeneration remain elusive, as well as the effects of
altered energy metabolism on microglial inflammatory
responses. This might be due to the paucity of suitable
models to investigate microglia function and the
challenging translation of animal models to humans.
Moreover, in vitro studies ofmicroglial activation should
be interpreted with caution, as the microglia phenotype
is highly dependent on the particular microenvironment
within the CNS. The present review gathers the still
limited knowledge regarding the link between alter-
ations in the energy metabolic profile of microglia and
disease mechanisms in neurodegenerative disorders.
In addition, the therapeutic potential of regulating
microglial energy metabolism is focused upon.Microglia, More Than Immune
Surveillance Cells
Microglia account for 10%–15% of non-neural
cells in the brain. They are generally described as
brain-resident immune cells which closely resemble
peripheral macrophages [1]. Several homeostatic
functions in the CNS can be ascribed to these highly
dynamic cells [20,21]. Among these, microglia are
indispensable for normal brain development, partic-
ipating in synapse pruning, neuronal survival and
synaptogenesis [22]. Relevant to their role as
immune sentinels, microglia express several im-
mune molecules, including integrins, toll-like recep-
tors, and triggering receptor expressed on myeloid
cells (TREM). Furthermore, microglia phagocytize
cells and cell debris as well as participate in
remodeling of the extracellular matrix [7,23–29]. In
line with this, microglia can acquire an ameboidmorphology that is associated with increased
phagocytosis. Microglia display remarkable plasticity
and are capable of responding to a vast array of
challenges [20]. Microglia activation in response to
infection and tissue damage involves specific
morphofunctional changes and represents a first-
line innate response. Conversely, chronic microglia
activation, particularly the cytotoxic action, has been
shown to have negative outcomes in conditions such
as stroke and neurodegenerative disorders
[6,30–34]. For instance, activation of microglia has
been implicated in the inflammatory alterations
observed in severe neurodegenerative disease
such as Alzheimer's disease (AD), Parkinson's
disease (PD), Huntington disease (HD), multiple
sclerosis (MS), and amyotrophic lateral sclerosis
(ALS) [8,19]. Moreover, in such conditions, microglia
are believed to act as effectors in the neuronal
degeneration. Whether protective or harmful, micro-
glial perpetual state of motion continuously scanning
the CNS imposes a large-energy requirement
(Fig. 1) [12].Brain Energy Metabolism in a Nutshell
Brain activity requires a large and continuous
energy supply. About 25% of glucose and 20% of the
oxygen consumed by the body are directed to
support cerebral function, although thebrain represents
only 2% of the total body weight [11,35]. The main
processes contributing to the high brain energy
demand include restoration and maintenance of the
ion gradients dissipated by signaling processes such
as action potentials, as well as neurotransmitter
turnover [11,35,36]. While glucose is the main energy
substrate of the adult brain, under certain conditions
such as development, starvation, and during intense
exercise, the brain is capable of utilizing additional
energy substrates, such as lactate [37,38] or ketone
bodies [39] As in any other cell type, glucose can
enter cells via specific glucose transporters (GLUTs).
Once in the cytosol, glucose is phosphorylated by
hexokinase to produce glucose-6-phosphate (G6P),
which can be processed into several metabolic
pathways. G6P can be metabolized through glycolysis
which gives rise to twomolecules of pyruvate, energy in
the form of ATP and reducing equivalents as nicotin-
amide adenine dinucleotide (NADH). Alternatively,
G6P can be processed in the pentose phosphate
pathway (PPP) subsequently leading to production of
reducing equivalents (NADPH). In PPP, G6P is
converted into ribulose 5-phosphate utilizing two
molecules of NAD+. Thus, when ample amount of
energy is required, the level of NADPH is reduced and
the pathway is activated to generate more reducing
equivalents. In astrocytes, G6P can be further used for
the synthesis of glycogen. Furthermore, several
metabolic intermediates produced in the brain from
Fig. 1. Microglia, more than immune surveillance cells. Microglia functions may represent a “double-edged sword.”
These cells are indispensable for normal CNS development and are capable of monitoring the brain environment for
clearance of harmful agents and dysfunctional cells. Conversely, during disease progression, microglia then turn into a
dysfunctional phenotype which ultimately becomes deleterious.
1832 Review: Microglial Metabolic Changes in Neurodegenerationglucose can subsequently be oxidized for energy
production (e.g., lactate, pyruvate, glutamate, or
acetate) [40]. Pyruvate can additionally be precursor
for lactate synthesis by the enzyme lactate dehydro-
genase (LDH). Lactate is mainly released into the
extracellular space via monocarboxylate transporters
(MCTs). Under aerobic conditions, pyruvate can then
enter mitochondria where it undergoes oxidative
decarboxylation to produce acetyl-Coenzyme A (ace-
tyl-CoA) and be further metabolized in the tricarboxylic
acid (TCA) cycle and oxidative phosphorylation,
consuming oxygen and further producing ATP and
CO2. In the TCA cycle, the reducing equivalents flavin
adenine dinucleotide (FADH2) and NADH are further
produced and transfer their electrons (and protons) to
molecular oxygen via mitochondrial electron transport
chain (ETC) located in the inner mitochondrial
membrane. The ETC comprises four enzyme com-
plexes (I–IV), and the transfer of electrons through
these complexes is accomplished by co-enzymes
ubiquinone and cytochrome C. During this process,
protons are transported across the inner mitochondrial
membrane from the matrix to the intermembrane
space to generate an electrochemical gradient. The
ATP synthase (complex V) harnesses the energy fromthe protons moving down its electrochemical gradient
to catalyze the phosphorylation of ADP, thereby
generating ATP. The complete oxidation of glucose in
the mitochondria produces larger amounts of energy in
the form of ATP (30–34 ATP molecules) compared to
glycolysis (2 ATP). Mitochondria are major metabolic
centers for ATP production in brain cells, and they are
crucially involved in amino acid metabolism, oxygen
metabolism, ROS production, and calcium handling
and are thus critical to cell viability. In addition,
mitochondria are regulators of cell death, a key feature
of neurodegeneration. Several lines of evidence
demonstrate that mitochondria have a central role in
ageing-related neurodegenerative diseases [41].
Moreover, a large number of disease-specific proteins
interact with mitochondria. Thus, targeting mitochon-
drial processes, including energy metabolism, ROS
generation, as well as abnormal protein interactions
with mitochondria, holds great therapeutic potential.Microglia Energy Metabolism
Microglial survival and function depends on
sufficient energy supply [42]. Microglia constantly
Fig. 2. Possible metabolic switch during microglia activation and the vicious cycle of sustained microglial activation,
neuroinflammation, and neurodegeneration. In the healthy adult brain, microglia are mostly in a “resting” state displaying
distinct morphological traits including a small soma and ramified morphology with dynamic processes used to monitor the
microenvironment. In response to insults, microglia rapidly become activated and reorganize their structure and functions
toward protection and repair responses. Microglial activation has been suggested to be associated with a metabolic switch
in favor of glycolysis and decreased oxidative phosphorylation (OXPHOS). The acute microglial neuroinflammatory
responses involve release of several inflammatory mediators such as cytokines and may trigger oxidative stress (ROS).
This acute response is thought to be beneficial to the CNS, as it can prevent further neuronal damage and promote repair
mechanisms. In contrast, chronic neuroinflammation may be detrimental because once activated, microglia can release
potentially harmful factors that may stimulate the activation of additional microglial cells in a self-renewing damaging
cascade. Under these conditions, mitochondria are a particularly vulnerable target of oxidative stress and proinflammatory
mediators that may damage essential mitochondrial components such as enzymes of the ETC and mtDNA.
Simultaneously, a primary mitochondrial dysfunction accompanied by elevated ROS production could induce microglial
activation. Interestingly, microglial activation and mitochondrial dysfunction have been proposed to trigger and perpetuate
molecular pathways leading to neuronal degeneration.
1833Review: Microglial Metabolic Changes in Neurodegenerationmove their processes through the brain parenchyma
scanning for abnormalities and making dynamic
contact with neuronal somata and synapses [28].
After tissue damage, microglia also extend their
processes and migrate to the injury site [43] where
they change retract their processes changing their
shape and phagocytose cells and other debris. It is
not completely understood whether glycolytic path-
ways or oxidative phosphorylation power microglial
motility and phagocytosis, but it can be speculated
that these processes represent a significant energy
demand in the brain [12].The bioenergetics of microglia in physiological
conditions have been elegantly revised by Ghosh et al.
[44]; hence, this will only be briefly addressed here.
Evidence indicates that microglia rely on both glycolytic
and oxidative energy metabolism depending on the
activation state [44,45]. A comparative transcriptional
profiling of genes related to energy metabolism in
neurons, astrocytes, and microglia of mouse brain
revealed that microglia express the set of genes
required for both glycolytic and oxidative energy
metabolism [46]. Non-activated microglia has been
suggested to rely mainly on oxidative phosphorylation
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conversely, has been shown to favor glycolysis. In
support of the later, increased lactate production and
decreased ATP production associated with mitochon-
drial function were detected in amicroglia cell line upon
activation with lipopolysaccharides [50,51].
Glucose seems to be the essential fuel for
microglia, although these cells are capable of
utilizing additional substrates for energy production.
Microglia are able to take up glucose and lactate
through various GLUTS (although GLUT3 seems to
be predominantly expressed) and MCTs, respec-
tively [45]. Glucose may follow a glycolytic fate and
TCA cycle processing thereafter. Microglia are also
capable of metabolizing ketone bodies such as
acetoacetate and β-hydroxybutyrate, which may act
as metabolic signals [52–54]. This emerging role of
ketone bodies in microglia metabolism is further
discussed in the following sections. Although lipid
metabolism is not prominent in the brain, it has been
suggested that microglia take up and process fatty
acids via lipoprotein lipase. Furthermore, microglia
express the long-chain fatty acyl-CoA synthetase,
which catalyzes the formation of fatty acyl-CoA that
in turn is β-oxidized into acetyl-CoA and can be
further metabolized in the TCA cycle [46]. Glutamine
is a key energy substrate for brain cells, particularly
neurons [55]. This vital amino acid may also serve as
an important energy substrate in microglia as it has
been shown that the glutamine receptors SLC1A5
and SLC38A1 are expressed in these cells enabling
them to take up glutamine [46]. Inside the mitochon-
dria, glutamine is converted to glutamate, which is
further metabolized by the enzyme glutamate
dehydrogenase to α-ketoglutarate, which can enter
the TCA cycle and fuel ATP production.
Mechanisms by which energy metabolism affects
microglia-derived inflammation are just starting to be
unraveled. However, mitochondrial function, glucose
availability, and glycolytic rate have been shown to
influence pro-inflammatory gene expression at both
transcriptional and posttranslational levels [44]. In
line with this, it was shown that activation of
adenosine monophosphate (AMP)-activated protein
kinase (AMPK), a metabolic sensor, reduced LPS-
induced inflammation in the microglial cell line BV-2
cells [56]. Furthermore, in primary microglia cultures,
2-deoxy-D-glucose, a blocker of the glycolytic path-
way, diminishes TNF-α and IL-6 production by
inhibiting nuclear factor kappa-light-chain-enhancer
of activated B cells (NF-κB) signaling [57].
Neuronal and non-neuronal cells including microg-
lia utilize the energy yielded in the form of ATP from
glucose metabolism for cell survival, generation of
key molecules involved in neurotransmission, and
maintenance of general brain homeostasis. Pertur-
bations in the tight regulation of energy metabolism
may be the pathophysiological substrate of many
brain disorders. Investigations to identify additionalconnections between microglia energy metabolism
and microglial function, particularly in neurodegen-
eration, are starting to emerge.Altered Brain Energy Metabolism in
Neurodegenerative Disorders
Neurodegenerative disorders are a broad spec-
trum of syndromes affecting the CNS. These are
characterized by progressive neuronal dystrophic
structural alterations, loss of function, and ultimately
cell death. At present, there is no curative treatment
for such disorders, and the drugs currently available
have imperceptible or limited effect on the clinical
course [58]. Among the most prevalent and devas-
tating neurodegenerative disorders are AD and PD,
while HD, MS, and ALS are less common. These
disorders share several pathological characteristics
at a subcellular level including abnormal protein
aggregation, failure in protein degradation pathways,
impaired axonal transport, and overall bioenergetic
and mitochondrial dysfunction [59]. A large body of
evidence indicates that brain metabolic alterations
strongly influence the genesis and progression of
neurodegenerative disorders. Functional neuroim-
aging studies including positron-emission tomogra-
phy (PET) analyses using fluoro-deoxyglucose
uptake into brain cells have shown reduced regional
glucose utilization in the brain of patients suffering
from AD, PD, ALS, and HD [16–18,60–62]. More-
over, epidemiological studies indicate that metabolic
disturbances and syndromes such as high blood
pressure, obesity, diabetes, and atherosclerosis
may be risk factors for dementia [63]. Therefore,
deficits in energy metabolism particularly glucose
hypometabolism and mitochondrial dysfunction are
highly regarded as early indicators of neurodegen-
erative disease pathology.
Notably, the studies summarized below are
representative evidence of alterations in brain
energy metabolism (neuronal and astrocytic metab-
olism) in several neurological conditions, and such
summary does not attempt to be a comprehensive
collection of the vast literature available regarding
this field (for an extensive review, the reader is
referred to Ref. [14]).
Dementia is an umbrella term for a set of
symptoms including prominent cognitive decline
that is often associated with aging. AD is the most
common cause of late-onset dementia causing as
many as 50% to 70% of all dementia cases [64]. AD
ethiopathology includes plaques of amyloid β (Aβ)
peptides and neurofibrillary tangles of hyperpho-
sphorylated tau protein. These are linked to synapse
loss and neuronal death, leading to cognitive decline
[65]. Compromised brain energy metabolism is a
prominent feature in aging and AD pathology [32].
Interestingly, alterations in expression levels and
1835Review: Microglial Metabolic Changes in Neurodegenerationactivities of transporters and metabolic enzymes
have been reported in this neurodegenerative
disorder. For instance, in mouse models of AD,
decreased GLUT1 levels were found to exacerbate
amyloid pathology, neurodegeneration, and cogni-
tive function [66]. Reduced levels of GLUT1 and
GLUT3 have been observed in the brain of AD
patients [67,68], which correlated with decreased
brain glucose uptake and subsequent cognitive
decline [69]. In addition, a dramatic loss of activity
of glycolytic enzymes such as phosphofructokinase,
phosphoglycerate mutase, aldolase, G6P isomer-
ase, and LDH was found in brain tissue of AD
patients compared to age-matched controls [70].
Moreover, pyruvate dehydrogenase complex [71],
cytochrome oxidase [72], and α-ketoglutarate dehy-
drogenase complex [73] were also seen to be
decreased in AD brains. Interestingly, ketogenic
substance and nicotinamide supplementation has
been effective to reduce Aβ and Tau pathologies and
to improve behavioral responses [74].
PD is characterized by progressive loss of
dopaminergic neurons in the substantia nigra pars
compacta and their projections to the caudate–
putamen of the basal ganglia, which play an
essential role in motor function [75]. Glucose
hypometabolism in PD brains has also been
documented using neuroimaging methods in pa-
tients [76]. Notably, mutations in genes associated
with early-onset inherited forms of PD (Parkin,
PINK1, LRRK2, α-synuclein) result in mitochondrial
dysfunction [77]. Furthermore, α-synuclein in plasma
has been shown to regulate glucose uptake [78].
Decreased levels of the PPP enzymes G6P-
dehydrogenase and 6-phosphogluconate dehydro-
genase have been detected at early stages in the
putamen and cerebellum of PD brains [79], while
G6P-isomerase has been identified as an altered
key participant in dopamine metabolism and degen-
eration in neurons derived from PD animal models
[80]. Interventions directed to improve mitochondrial
bioenergetics have been shown to ameliorate
neuropathology and motor deficits in animal models
of PD [81].
ALS (Lou Gehrig's disease) is the most common
adult motor neuron disease. It has been shown that
ALS patients display increased systemic energy
expenditure at rest and are hypercatabolic [82]. In
line with this, a recent metabolomics analysis
identified increased glycolysis and deficits in amino
acid metabolism in a cellular model of ALS. It has
been hypothesized that the overall increase in
energy demand may reflect major cellular activity
to stimulate CNS and muscle repair in an attempt to
control the ALS neurodegenerative process [83]. To
warrant high levels of ATP production, mitochondria
activity and number may increase resulting in
enhanced production and release of ROS, which
potentially could reach neurotoxic levels [84]. Inaddition, metabolic alterations including glucose
intolerance [85] and insulin resistance [86] have
been reported in ALS patients and animal models as
well as alterations in blood–brain barrier properties
and molecules [87] resulting in increased permeabil-
ity of the blood–brain barrier and therefore abnormal
composition of the cerebrospinal fluid. Together,
these findings indicate that altered metabolic ho-
meostasis is associated with ALS pathology.
Although MS is perceived to result from an
autoimmune effect of T cells targeting the myelin
sheath, MS is a complex CNS disorder in which
impaired energy metabolism, particularly mitochon-
drial dysfunction, has a substantial role [60,88]. Early
studies suggesting the involvement of defective
pyruvate metabolism in MS were performed by
Jones et al. [89] in the 1950s. Elevated blood
pyruvate levels were found in both fasting and
postprandial periods in MS patients with relapse
[89]. Later, increased pyruvate levels and α-
ketoglutarate were also observed in this disease
[90]. In addition, the association between disturbed
pyruvate metabolism and MS progression was
further strengthened by increased levels of TCA
cycle metabolites such as α-ketoglutarate and citrate
found in MS patients [91,92]. Increased activity of
metabolic enzymes including enolase, pyruvate
kinase, LDH, and aldolase in the brain of MS
patients has also been detected [93]. Several
mitochondrial abnormalities have been identified in
MS. For instance, it has been observed that both the
number and activity of mitochondria in MS plaques
are increased [94]. Moreover, mitochondrial proteins
are overexpressed in MS lesions where diminished
ATP synthase expression has been detected [95].
Specifically, complex IV activity was significantly
increased [96].
HD is a genetic neurodegenerative disorder linked
to trinucleotide (CAG) repeat expansions in the
huntingtin gene. HD is associated with degeneration
and loss of neurons in the striatum causing
incessant involuntary movements and motor impair-
ments [97]. Using system-wide analysis of the
spatial proteome combined with mass spectrometric
analysis, we have recently identified alterations in
key proteins related to brain energy metabolism,
particularly, glia metabolism in a mouse model of HD
[15]. Striatal metabolism has been shown to be
decreased prior to atrophy, and interestingly, dis-
ease progression is strongly correlated with glucose
hypometabolism [98]. In line with this, it has been
observed that at early stages of striatum degener-
ation HD patients display decreased brain glucose
uptake [99]. Expression of GLUT3 has been shown
to be diminished in the striatum and cortex of HD
mice compared to wild-type mice [100]. Interestingly,
increasing copy numbers of the gene encoding
GLUT3 correlated with a delayed disease onset
in HD patients, and overexpression of GLUT3,
1836 Review: Microglial Metabolic Changes in Neurodegenerationphosphofructokinase, and G6P-dehydrogenase pro-
tects against development of HD phenotypes in
animal models [101]. Finally, evidence suggests that
up-regulation of sirtuins, which have been proposed
to act as metabolic sensors, may protect striatal
neurons against degeneration possibly by preserv-
ing mitochondrial function [102,103]. These studies
indicate that interventions that improve neuronal
bioenergetics may ameliorate HD pathogenesis.
Conclusive evidence strongly supports that altered
brain metabolic homeostasis plays a major role in
the initiation and progression of neurodegenerative
disorders. However, the wealth of knowledge re-
garding brain energy metabolism function and
dysfunction in disease context has been mainly
focus on the neuronal and astrocytic compartment,
while the intricacies of microglial energy metabolism
in neurodegeneration have just begun to be
discovered.Microglial Metabolism and
Neurodegenerative Disorders
Microglia and metabolism in AD
”It is well recognized that neurodegenerative
diseases are accompanied by deficits in brain
energy metabolism [13–15,32]. Neuroinflammation,
particularly derived from microglia activation, is also
believed to contribute to such brain disorders.
However, the bioenergetic mechanisms involved in
the neurotoxic or neuroprotective functions of
microglia are still unresolved and the studies
available in this area are limited.
AD pathophysiology has been associated with
increased oxidative stress and neuroinflammation,
process in which microglia has been significantly
implicated [6]. During disease progression, microglia
may assume a useful role, and then progress into a
dysfunctional phenotype, which ultimately becomes
detrimental. In support of a direct link between
aberrant microglial functions and AD, recent tran-
scriptomic studies of microglia in normal and Aβ-
mice identified microglial subpopulations defined as
disease-associated microglia (DAM). DAMs are
located around Aβ plaques and display dysregulated
expression of housekeeping, and host-defense
genes [104]. At present, little is known about the
link between microglia bioenergetics, neuroinflam-
mation, and brain energy failure in AD neurodegen-
eration. Recently, sophisticated neuroimaging
studies using multiple-tracer PET revealed the
apparent coexistence of neuroinflammation and
elevated glucose consumption in animal models of
AD pathology and brain ischemia [105,106]. This
may seem paradoxical as it has been consistently
demonstrated that glucose hypometabolism is adisease marker of the AD brain. Backes et al. [105]
claimed that inflammatory cells in diseased brains
managed to consume comparable amounts of
glucose per time and tissue volume as neurons
and astrocytes consume during healthy conditions.
Given that brain immune cells are capable of
harvesting high amounts of glucose and non-
oxidatively metabolize the substrate in reduced
oxygen and glucose conditions, those observations
suggest that energy metabolism of brain inflamma-
tory cells (including microglia) may be masking
metabolic deficits in regions with neuronal damage.
Previous studies have shown that Aβ-plaques in
the AD brain elicit inflammatory responses, which
may also be reflected systemically in plasma.
Treatment with AD plasma was found to affect
cellular bioenergetics in a microglial cell line by up-
regulating glycolytic flux and enzyme expression
arguably to compensate for mitochondrial dysfunc-
tion and decreased cell viability [107]. This obser-
vation supports the increasing body of evidence that
inflammation and energy metabolism are closely
linked phenomena in which microglial energetics
may also have a significant contribution.
Modulating microglia activity by controlling micro-
glial energy metabolismmay represent an innovative
approach to hinder neurodegenerative processes. In
support of this, targeting the microglial potassium
(KATP) channels has been shown to be effective in
controlling inflammatory microglia activation, avoid-
ing its toxic phenotype though a mitochondria-
dependent mechanism [108]. Recently, the trigger-
ing receptor expressed on myeloid cells-2 (TREM-2)
expressed in microglia has received attention in the
field of neurodegeneration as coding variants that
increase the risk of AD and other neurodegenerative
diseases have been identified [109,110]. A recent
study combining metabolomics, RNA sequencing,
and system analysis showed that microglia of
TREM2-deficient mice with AD-like pathology and
of AD patients carrying TREM2 risk variants display
anomalous autophagy linked to defective mamma-
lian target of rapamycin (mTOR) signaling, which
affects ATP levels and biosynthetic pathways.
These findings indicate that TREM2 enables micro-
glial responses by sustaining cellular energetic and
biosynthetic metabolism in AD [111].
Microglia and metabolism in PD
Pioneer studies by McGeer et al. [112] showed the
involvement of activated microglia in PD. In the brain
from PD patients, high levels of reactive microglia
were found in the substantia nigra and putamen
[112], and it has been shown that activated microglia
may exacerbate neurodegeneration in PD brains
[113]. In addition, the exposure of human neurome-
lanin discharged from damaged dopamine neurons
increases the release of pro-inflammatory molecules
1837Review: Microglial Metabolic Changes in Neurodegenerationin microglial cultures [31]. Recently, PET studies
revealed that PD patients display cortical microglial
activation and decreased brain glucose metabolism
in early stages of the disease [17] as well as
increased microglial activation in the basal ganglia
involved in PD pathology [17,114,115]. These
findings imply that microglial activation may be a
contributing factor in disease progression. However,
studies addressing the potential involvement of
microglial energy metabolism in PD are scarce.
The mechanism of microglia-mediated neurotox-
icity in PD is believed to be linked to the generation of
oxidative insults from microglia. In the last decade,
novel regulatory roles for microglia in PD pathology
have been discovered. For instance, metabolomics
profiling in cultured microglia demonstrated that α-
synuclein-activated microglia produce cytoskeletal,
inflammatory, redox-active, and regulatory proteins.
Importantly in the metabolic context, α-synuclein
stimulation induced metabolic responses in microg-
lia that modulate the glutamate–glutamine cycle.
Specifically, a decrease in intracellular glutamate
and an increase in the extracellular concentrations of
the amino acid were observed [116]. The glutamate–
glutamine cycle is crucial for bioenergetic homeo-
stasis and neurotransmission [117]. In addition,
multiple lines of evidence suggest that neurotoxic
levels of glutamate in the extracellular space also
play a complex role in neurodegenerative diseases
[118]. It has been shown that activated microglia
may secrete large amounts of glutamate. In line with
this, studies using microglia isolated from primary
mixed glial cell cultures from mice brain showed that
neurotoxicity induced by activated microglia is
primarily mediated by released glutamate followed
by activation of the glutamate receptor subtype, N-
methyl-D-aspartate (NMDA) receptor and signaling
[119]. Following microglia glutamate secretion and
NMDA receptor activation, neuronal mitochondrial
respiration was observed to be impaired leading to
neuronal energy loss and ultimately cell death [119].
Of note, however, is the fact that in vivo evidence
that microglial release of glutamate is specifically
causing neuronal death is lacking.
A recent study using an animal model of PD
reported that ethyl pyruvate (EP), a derivative of
pyruvate, inhibits microglial activation in vivo in the
substantia nigra, suggesting that EP may have
therapeutic importance in PD regarding microglia-
derived oxidative damage [120].
As mentioned before, activated microglia produce
several pro-inflammatory enzymes and cytokines
that could potentially lead to neuronal damage. It has
been suggested that inhibition of microglial over-
activation may be a potential therapeutic strategy to
prevent the progression of PD. β-Hydroxybutyrate
has been shown to suppress lipopolysaccharide
(LPS)-induced inflammation in a microglial cell line
BV-2 and to protect dopaminergic neurons [121].Furthermore, β-hydroxybutyric acid concentration-
dependently attenuated the LPS-induced decrease
in dopamine uptake and loss of tyrosine
hydroxylase-immunoreactive neurons in a primary
mesencephalic neuron/glia mixed culture. β-Hydro-
xybutyric acid treatment significantly improved the
motor dysfunction in a rat PD model induced by
intranigral injection of LPS. The beneficial effect of β-
hydroxybutyric was attributed to the inhibition of
microglial over-activation and protection of dopami-
nergic neurons in the substantia nigra. This effect
was shown to be mediated by G-protein-coupled
receptor 109A (GPR109A) and involved the NF-κB
signaling pathway, thus inhibiting pro-inflammatory
enzyme (iNOS and COX-2) and cytokine (TNF-α, IL-
1β, and IL-6) production [52].
Novel potential approaches to regulate microglial
immunomodulation in PD include metabolic targets
such as AMPK, a critical enzyme in cellular energy
homeostasis and glycogen synthase kinase-3β, an
enzyme that mediates microglial migration and
inflammation-induced neurotoxicity [122,123].
Microglia energy metabolism in HD and other
rare disorders
Despite the critical role of microglia in brain
pathologies, limited knowledge is available regard-
ing if and how microglial energy metabolism plays a
role in neurodegenerative diseases such HD, ALS,
and MS, and the cellular mechanisms that govern
microglia bioenergetics are just beginning to be
defined in those diseases. Since neuroinflammation
is an important feature of these disorders and it has
been suggested that energy metabolism affects the
pro-inflammatory response in microglia, it can be
speculated that the bioenergetics of microglia are
somehow involved in these brain disease and the
therapeutic potential of targeting microglia metabo-
lism requires comprehensive investigation. For
instance, in a model of HD, it was found that the
mechanisms involved in pyruvate-mediated neuro-
protection of striatal neurons include inhibition of
microglial activation [124]. It is now recognized that
ALS pathophysiology includes chronic microglial
activation particularly in the surroundings of deteri-
orating motor neurons [125]. Energy deficits and
oxidative stress are critically implicated in the
pathogenesis of MS. However, there is still a need
for investigating microglia bioenergetics in this
disorder.
Finally, age is the main risk factor for many
neurodegenerative diseases. Therefore, aging is a
critical process for examination in order to under-
stand the progression and potential intervention in
major brain disorders. Specific changes in the
metabolic profile of microglia have been document-
ed in aging. For instance, a study using mass
spectrometry-based proteomics to compare primary
1838 Review: Microglial Metabolic Changes in Neurodegenerationmicroglia from young and aged animals revealed
alterations in proteins involved in inflammatory
signaling, mitochondrial function, and cellular me-
tabolism, particularly proteins responsible for the
breakdown of amino acids and the conversion of
ketone bodies into succinyl-CoA. The findings are
claimed to indicate that microglia from aged mice
display changes in energy regulation that might
underlie the alterations in inflammatory signaling
[126]. However, the possibility that changes in
energy regulation are a result of the exacerbated
inflammatory environment cannot be discarded.
Neuroinflammation and oxidative stress have been
associated with non-pathological aging in humans
and animal models. Functional decline of mitochon-
dria in microglia has been shown to produce an
exacerbated generation of ROS and inflammatory
mediators. Accumulation of mitochondrial DNA
oxidative damage in microglia during aging pro-
motes ROS production, which in turn may also
increase oxidative stress. Many of these changes
are also observed in neurodegenerative condi-
tions, and thus, it is unclear whether these
alterat ions are reactive to the underlying
pathophysiology.Conclusions and Future Directions
Microglial pleiotropic functions range from CNS
development and homeostasis to active surveillance
of the brain and prompt immune response to injury
and infection. Microglia (dys)functions, particularly
neuroinflammatory actions, have been identify as a
key participant in neurodegenerative disorders.
These disorders are accompanied by well-
documented deficits in brain energy metabolism,
although the current knowledge is based mainly on
neurons and astrocytes. Furthermore, analysis of
the molecular mechanisms relevant for microglia
reprogramming toward regenerative functions points
to the crucial role of energy metabolism in shaping
microglial functions. Manipulation of metabolic path-
ways might provide new therapeutic strategies to
prevent the detrimental effects of abnormal inflam-
matory microglia and to control exacerbated inflam-
mation in brain disorders (see Fig. 2). Therefore,
current and future research regarding microglia-
specific metabolic changes in neurodegeneration
should be directed to further understand energy
metabolic pathways in microglia, molecular mecha-
nism involved in phenotype selection and to unravel
how energy metabolism influences inflammatory
process. One approach that may prove to be
valuable is the use and development of improved
in vitro microglia models that more closely recapit-
ulate healthy and disease states. Such models are
emerging and include microglia derived from human-
induced pluripotent stem cells (hiPSCs), which holdgreat promise particularly to study specific disease
phenotypes. However, hiPSCs have the main caveat
that they do not reflect the effects of aging. In addition,
one of the main challenges is to accurately generate
the different microglial activation phenotypes and the
complex interplay between several cell types in brain
which are difficult to model in cell culture. Finally, as
our understanding of microglia physiology increases,
they key involvement of microglial bioenergetics in
neurodegeneration is being unravel and novel thera-
peutic avenues in neurodegenerative disorders will be
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